APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biocompatibility Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biocompatibility Testing Market Analysis and Forecast 2026-2032

3 May 2026184 pages

Choose your research edition.

Industry ResearchBiocompatibility Testing Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Biocompatibility Testing Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Biocompatibility Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biocompatibility Testing Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Biocompatibility Testing Market Analysis and Forecast 2026-2032184 pages · $4,950 USD

Market perspective

The global Biocompatibility Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biocompatibility Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biocompatibility Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biocompatibility Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biocompatibility Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biocompatibility Testing include Eurofins, Charles River, TUV SUD, Intertek Group, WuXi AppTec, LabCorp, Syensqo, SGS and Nelson Labs, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biocompatibility Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biocompatibility Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Biocompatibility Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biocompatibility Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biocompatibility Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biocompatibility Testing revenue, projected growth trends, production technology, application and end-user industry.

Biocompatibility Testing Segment by Company

Eurofins

Charles River

TUV SUD

Intertek Group

WuXi AppTec

LabCorp

Syensqo

SGS

Nelson Labs

Pacific BioLabs

Vantage MedTech

Cormica Lab (Wickham Micro)

CTI

CIRS

Shenzhen Advanced

Kerbio

CAS Testing

PONY Medicine

Tigermed

King Rock

Biocompatibility Testing Segment by Type

Cytotoxicity

Sensitization

Irritant

Pyrogen

Other

Biocompatibility Testing Segment by Application

Clinical

Non-clinical

Biocompatibility Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biocompatibility Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biocompatibility Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biocompatibility Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biocompatibility Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biocompatibility Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biocompatibility Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biocompatibility Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cytotoxicity Major Player Table 3. Sensitization Major Player Table 4. Irritant Major Player Table 5. Pyrogen Major Player Table 6. Other Major Player Table 7. Global Biocompatibility Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinical Major Player Table 9. Non-clinical Major Player Table 10. Biocompatibility Testing Industry Trends Table 11. Biocompatibility Testing Industry Drivers Table 12. Biocompatibility Testing Industry Opportunities and Challenges Table 13. Biocompatibility Testing Industry Restraints Table 14. Global Biocompatibility Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Biocompatibility Testing Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Biocompatibility Testing Market Share by Region (2021-2026) Table 17. Global Biocompatibility Testing Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Biocompatibility Testing Market Share by Region (2027-2032) Table 19. Global Biocompatibility Testing Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Biocompatibility Testing Revenue Market Share by Players (2021-2026) Table 21. Global Biocompatibility Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Biocompatibility Testing Key Players Headquarters & Area Served Table 23. Global Biocompatibility Testing Players, Product Type & Application Table 24. Global Biocompatibility Testing Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Biocompatibility Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Biocompatibility Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biocompatibility Testing Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Biocompatibility Testing Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Biocompatibility Testing Revenue Market Share by Type (2021-2026) Table 31. Global Biocompatibility Testing Revenue Market Share by Type (2027-2032) Table 32. Global Biocompatibility Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Biocompatibility Testing Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Biocompatibility Testing Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Biocompatibility Testing Revenue Market Share by Application (2021-2026) Table 36. Global Biocompatibility Testing Revenue Market Share by Application (2027-2032) Table 37. Eurofins Company Information Table 38. Eurofins Business Overview Table 39. Eurofins Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Eurofins Biocompatibility Testing Product Portfolio Table 41. Eurofins Recent Development Table 42. Charles River Company Information Table 43. Charles River Business Overview Table 44. Charles River Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Charles River Biocompatibility Testing Product Portfolio Table 46. Charles River Recent Development Table 47. TUV SUD Company Information Table 48. TUV SUD Business Overview Table 49. TUV SUD Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. TUV SUD Biocompatibility Testing Product Portfolio Table 51. TUV SUD Recent Development Table 52. Intertek Group Company Information Table 53. Intertek Group Business Overview Table 54. Intertek Group Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Intertek Group Biocompatibility Testing Product Portfolio Table 56. Intertek Group Recent Development Table 57. WuXi AppTec Company Information Table 58. WuXi AppTec Business Overview Table 59. WuXi AppTec Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. WuXi AppTec Biocompatibility Testing Product Portfolio Table 61. WuXi AppTec Recent Development Table 62. LabCorp Company Information Table 63. LabCorp Business Overview Table 64. LabCorp Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. LabCorp Biocompatibility Testing Product Portfolio Table 66. LabCorp Recent Development Table 67. Syensqo Company Information Table 68. Syensqo Business Overview Table 69. Syensqo Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Syensqo Biocompatibility Testing Product Portfolio Table 71. Syensqo Recent Development Table 72. SGS Company Information Table 73. SGS Business Overview Table 74. SGS Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. SGS Biocompatibility Testing Product Portfolio Table 76. SGS Recent Development Table 77. Nelson Labs Company Information Table 78. Nelson Labs Business Overview Table 79. Nelson Labs Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Nelson Labs Biocompatibility Testing Product Portfolio Table 81. Nelson Labs Recent Development Table 82. Pacific BioLabs Company Information Table 83. Pacific BioLabs Business Overview Table 84. Pacific BioLabs Biocompatibility Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Pacific BioLabs Biocompatibility Testing Product Portfolio Table 86. Pacific BioLabs Recent Development Table 87. Vantage MedTech Company Information Table 88. Vantage MedTech Business Overview Table 89. Vantage MedTech Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Vantage MedTech Biocompatibility Testing Product Portfolio Table 91. Vantage MedTech Recent Development Table 92. Cormica Lab (Wickham Micro) Company Information Table 93. Cormica Lab (Wickham Micro) Business Overview Table 94. Cormica Lab (Wickham Micro) Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Cormica Lab (Wickham Micro) Biocompatibility Testing Product Portfolio Table 96. Cormica Lab (Wickham Micro) Recent Development Table 97. CTI Company Information Table 98. CTI Business Overview Table 99. CTI Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. CTI Biocompatibility Testing Product Portfolio Table 101. CTI Recent Development Table 102. CIRS Company Information Table 103. CIRS Business Overview Table 104. CIRS Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. CIRS Biocompatibility Testing Product Portfolio Table 106. CIRS Recent Development Table 107. Shenzhen Advanced Company Information Table 108. Shenzhen Advanced Business Overview Table 109. Shenzhen Advanced Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Shenzhen Advanced Biocompatibility Testing Product Portfolio Table 111. Shenzhen Advanced Recent Development Table 112. Kerbio Company Information Table 113. Kerbio Business Overview Table 114. Kerbio Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Kerbio Biocompatibility Testing Product Portfolio Table 116. Kerbio Recent Development Table 117. CAS Testing Company Information Table 118. CAS Testing Business Overview Table 119. CAS Testing Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. CAS Testing Biocompatibility Testing Product Portfolio Table 121. CAS Testing Recent Development Table 122. PONY Medicine Company Information Table 123. PONY Medicine Business Overview Table 124. PONY Medicine Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. PONY Medicine Biocompatibility Testing Product Portfolio Table 126. PONY Medicine Recent Development Table 127. Tigermed Company Information Table 128. Tigermed Business Overview Table 129. Tigermed Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Tigermed Biocompatibility Testing Product Portfolio Table 131. Tigermed Recent Development Table 132. King Rock Company Information Table 133. King Rock Business Overview Table 134. King Rock Biocompatibility Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. King Rock Biocompatibility Testing Product Portfolio Table 136. King Rock Recent Development Table 137. North America Biocompatibility Testing Revenue by Type (2021-2026) & (US$ Million) Table 138. North America Biocompatibility Testing Revenue by Type (2027-2032) & (US$ Million) Table 139. North America Biocompatibility Testing Revenue by Application (2021-2026) & (US$ Million) Table 140. North America Biocompatibility Testing Revenue by Application (2027-2032) & (US$ Million) Table 141. North America Biocompatibility Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Biocompatibility Testing Revenue by Country (2021-2026) & (US$ Million) Table 143. North America Biocompatibility Testing Revenue by Country (US$ Million) & (2027-2032) Table 144. Europe Biocompatibility Testing Revenue by Type (2021-2026) & (US$ Million) Table 145. Europe Biocompatibility Testing Revenue by Type (2027-2032) & (US$ Million) Table 146. Europe Biocompatibility Testing Revenue by Application (2021-2026) & (US$ Million) Table 147. Europe Biocompatibility Testing Revenue by Application (2027-2032) & (US$ Million) Table 148. Europe Biocompatibility Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Biocompatibility Testing Revenue by Country (2021-2026) & (US$ Million) Table 150. Europe Biocompatibility Testing Revenue by Country (US$ Million) & (2027-2032) Table 151. China Biocompatibility Testing Revenue by Type (2021-2026) & (US$ Million) Table 152. China Biocompatibility Testing Revenue by Type (2027-2032) & (US$ Million) Table 153. China Biocompatibility Testing Revenue by Application (2021-2026) & (US$ Million) Table 154. China Biocompatibility Testing Revenue by Application (2027-2032) & (US$ Million) Table 155. Asia Biocompatibility Testing Revenue by Type (2021-2026) & (US$ Million) Table 156. Asia Biocompatibility Testing Revenue by Type (2027-2032) & (US$ Million) Table 157. Asia Biocompatibility Testing Revenue by Application (2021-2026) & (US$ Million) Table 158. Asia Biocompatibility Testing Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Biocompatibility Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Biocompatibility Testing Revenue by Region (US$ Million) & (2021-2026) Table 161. Asia Biocompatibility Testing Revenue by Region (US$ Million) & (2027-2032) Table 162. SAMEA Biocompatibility Testing Revenue by Type (2021-2026) & (US$ Million) Table 163. SAMEA Biocompatibility Testing Revenue by Type (2027-2032) & (US$ Million) Table 164. SAMEA Biocompatibility Testing Revenue by Application (2021-2026) & (US$ Million) Table 165. SAMEA Biocompatibility Testing Revenue by Application (2027-2032) & (US$ Million) Table 166. SAMEA Biocompatibility Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. SAMEA Biocompatibility Testing Revenue by Country (2021-2026) & (US$ Million) Table 168. SAMEA Biocompatibility Testing Revenue by Country (US$ Million) & (2027-2032) Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Biocompatibility Testing Image Figure 2. Global Biocompatibility Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biocompatibility Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cytotoxicity Image Figure 5. Sensitization Image Figure 6. Irritant Image Figure 7. Pyrogen Image Figure 8. Other Image Figure 9. Global Biocompatibility Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Biocompatibility Testing Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinical Image Figure 12. Non-clinical Image Figure 13. Global Biocompatibility Testing Market Size (US$ Million) & (2021-2032) Figure 14. Global Biocompatibility Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Biocompatibility Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Biocompatibility Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Biocompatibility Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biocompatibility Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Biocompatibility Testing Revenue Market Share by Type (2021-2032) Figure 21. Global Biocompatibility Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Biocompatibility Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Biocompatibility Testing Revenue Market Share by Application (2021-2032) Figure 24. North America Biocompatibility Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Biocompatibility Testing Revenue Share by Type (2021-2032) Figure 26. North America Biocompatibility Testing Revenue Share by Application (2021-2032) Figure 27. North America Biocompatibility Testing Revenue Share by Country (2021-2032) Figure 28. United States Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Biocompatibility Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Biocompatibility Testing Revenue Share by Type (2021-2032) Figure 33. Europe Biocompatibility Testing Revenue Share by Application (2021-2032) Figure 34. Europe Biocompatibility Testing Revenue Share by Country (2021-2032) Figure 35. Germany Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Biocompatibility Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Biocompatibility Testing Revenue Share by Type (2021-2032) Figure 45. China Biocompatibility Testing Revenue Share by Application (2021-2032) Figure 46. Asia Biocompatibility Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Biocompatibility Testing Revenue Share by Type (2021-2032) Figure 48. Asia Biocompatibility Testing Revenue Share by Application (2021-2032) Figure 49. Asia Biocompatibility Testing Revenue Share by Region (2021-2032) Figure 50. Japan Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Biocompatibility Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Biocompatibility Testing Revenue Share by Type (2021-2032) Figure 58. SAMEA Biocompatibility Testing Revenue Share by Application (2021-2032) Figure 59. SAMEA Biocompatibility Testing Revenue Share by Country (2021-2032) Figure 60. Brazil Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Biocompatibility Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Cytotoxicity
  • Sensitization
  • Irritant
  • Pyrogen
  • Other
Applications
  • Clinical
  • Non-clinical
Companies covered
  • Eurofins
  • Charles River
  • TUV SUD
  • Intertek Group
  • WuXi AppTec
  • LabCorp
  • Syensqo
  • SGS
  • Nelson Labs
  • Pacific BioLabs
  • Vantage MedTech
  • Cormica Lab (Wickham Micro)
  • CTI
  • CIRS
  • Shenzhen Advanced
  • Kerbio
  • CAS Testing
  • PONY Medicine
  • Tigermed
  • King Rock

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biocompatibility Testing Market by Type
  3. 1.2.1 Global Biocompatibility Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cytotoxicity
  5. 1.2.3 Sensitization
  6. 1.2.4 Irritant
  7. 1.2.5 Pyrogen
  8. 1.2.6 Other
  9. 1.3 Biocompatibility Testing Market by Application
  10. 1.3.1 Global Biocompatibility Testing Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinical
  12. 1.3.3 Non-clinical
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Biocompatibility Testing Market Dynamics
  1. 2.1 Biocompatibility Testing Industry Trends
  2. 2.2 Biocompatibility Testing Industry Drivers
  3. 2.3 Biocompatibility Testing Industry Opportunities and Challenges
  4. 2.4 Biocompatibility Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biocompatibility Testing Market Perspective (2021-2032)
  2. 3.2 Global Biocompatibility Testing Growth Trends by Region
  3. 3.2.1 Global Biocompatibility Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biocompatibility Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Biocompatibility Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biocompatibility Testing Revenue by Players
  2. 4.1.1 Global Biocompatibility Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Biocompatibility Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biocompatibility Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biocompatibility Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biocompatibility Testing Key Players Headquarters & Area Served
  7. 4.4 Global Biocompatibility Testing Players, Product Type & Application
  8. 4.5 Global Biocompatibility Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biocompatibility Testing Market CR5 and HHI
  11. 4.6.3 2025 Biocompatibility Testing Tier 1, Tier 2, and Tier 3
5 Biocompatibility Testing Market Size by Type
  1. 5.1 Global Biocompatibility Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biocompatibility Testing Revenue by Type (2021-2032)
  3. 5.3 Global Biocompatibility Testing Revenue Market Share by Type (2021-2032)
6 Biocompatibility Testing Market Size by Application
  1. 6.1 Global Biocompatibility Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biocompatibility Testing Revenue by Application (2021-2032)
  3. 6.3 Global Biocompatibility Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eurofins
  2. 7.1.1 Eurofins Company Information
  3. 7.1.2 Eurofins Business Overview
  4. 7.1.3 Eurofins Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eurofins Biocompatibility Testing Product Portfolio
  6. 7.1.5 Eurofins Recent Developments
  7. 7.2 Charles River
  8. 7.2.1 Charles River Company Information
  9. 7.2.2 Charles River Business Overview
  10. 7.2.3 Charles River Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Charles River Biocompatibility Testing Product Portfolio
  12. 7.2.5 Charles River Recent Developments
  13. 7.3 TUV SUD
  14. 7.3.1 TUV SUD Company Information
  15. 7.3.2 TUV SUD Business Overview
  16. 7.3.3 TUV SUD Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 TUV SUD Biocompatibility Testing Product Portfolio
  18. 7.3.5 TUV SUD Recent Developments
  19. 7.4 Intertek Group
  20. 7.4.1 Intertek Group Company Information
  21. 7.4.2 Intertek Group Business Overview
  22. 7.4.3 Intertek Group Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Intertek Group Biocompatibility Testing Product Portfolio
  24. 7.4.5 Intertek Group Recent Developments
  25. 7.5 WuXi AppTec
  26. 7.5.1 WuXi AppTec Company Information
  27. 7.5.2 WuXi AppTec Business Overview
  28. 7.5.3 WuXi AppTec Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 WuXi AppTec Biocompatibility Testing Product Portfolio
  30. 7.5.5 WuXi AppTec Recent Developments
  31. 7.6 LabCorp
  32. 7.6.1 LabCorp Company Information
  33. 7.6.2 LabCorp Business Overview
  34. 7.6.3 LabCorp Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 LabCorp Biocompatibility Testing Product Portfolio
  36. 7.6.5 LabCorp Recent Developments
  37. 7.7 Syensqo
  38. 7.7.1 Syensqo Company Information
  39. 7.7.2 Syensqo Business Overview
  40. 7.7.3 Syensqo Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Syensqo Biocompatibility Testing Product Portfolio
  42. 7.7.5 Syensqo Recent Developments
  43. 7.8 SGS
  44. 7.8.1 SGS Company Information
  45. 7.8.2 SGS Business Overview
  46. 7.8.3 SGS Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 SGS Biocompatibility Testing Product Portfolio
  48. 7.8.5 SGS Recent Developments
  49. 7.9 Nelson Labs
  50. 7.9.1 Nelson Labs Company Information
  51. 7.9.2 Nelson Labs Business Overview
  52. 7.9.3 Nelson Labs Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Nelson Labs Biocompatibility Testing Product Portfolio
  54. 7.9.5 Nelson Labs Recent Developments
  55. 7.10 Pacific BioLabs
  56. 7.10.1 Pacific BioLabs Company Information
  57. 7.10.2 Pacific BioLabs Business Overview
  58. 7.10.3 Pacific BioLabs Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Pacific BioLabs Biocompatibility Testing Product Portfolio
  60. 7.10.5 Pacific BioLabs Recent Developments
  61. 7.11 Vantage MedTech
  62. 7.11.1 Vantage MedTech Company Information
  63. 7.11.2 Vantage MedTech Business Overview
  64. 7.11.3 Vantage MedTech Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Vantage MedTech Biocompatibility Testing Product Portfolio
  66. 7.11.5 Vantage MedTech Recent Developments
  67. 7.12 Cormica Lab (Wickham Micro)
  68. 7.12.1 Cormica Lab (Wickham Micro) Company Information
  69. 7.12.2 Cormica Lab (Wickham Micro) Business Overview
  70. 7.12.3 Cormica Lab (Wickham Micro) Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Cormica Lab (Wickham Micro) Biocompatibility Testing Product Portfolio
  72. 7.12.5 Cormica Lab (Wickham Micro) Recent Developments
  73. 7.13 CTI
  74. 7.13.1 CTI Company Information
  75. 7.13.2 CTI Business Overview
  76. 7.13.3 CTI Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  77. 7.13.4 CTI Biocompatibility Testing Product Portfolio
  78. 7.13.5 CTI Recent Developments
  79. 7.14 CIRS
  80. 7.14.1 CIRS Company Information
  81. 7.14.2 CIRS Business Overview
  82. 7.14.3 CIRS Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  83. 7.14.4 CIRS Biocompatibility Testing Product Portfolio
  84. 7.14.5 CIRS Recent Developments
  85. 7.15 Shenzhen Advanced
  86. 7.15.1 Shenzhen Advanced Company Information
  87. 7.15.2 Shenzhen Advanced Business Overview
  88. 7.15.3 Shenzhen Advanced Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Shenzhen Advanced Biocompatibility Testing Product Portfolio
  90. 7.15.5 Shenzhen Advanced Recent Developments
  91. 7.16 Kerbio
  92. 7.16.1 Kerbio Company Information
  93. 7.16.2 Kerbio Business Overview
  94. 7.16.3 Kerbio Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Kerbio Biocompatibility Testing Product Portfolio
  96. 7.16.5 Kerbio Recent Developments
  97. 7.17 CAS Testing
  98. 7.17.1 CAS Testing Company Information
  99. 7.17.2 CAS Testing Business Overview
  100. 7.17.3 CAS Testing Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  101. 7.17.4 CAS Testing Biocompatibility Testing Product Portfolio
  102. 7.17.5 CAS Testing Recent Developments
  103. 7.18 PONY Medicine
  104. 7.18.1 PONY Medicine Company Information
  105. 7.18.2 PONY Medicine Business Overview
  106. 7.18.3 PONY Medicine Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  107. 7.18.4 PONY Medicine Biocompatibility Testing Product Portfolio
  108. 7.18.5 PONY Medicine Recent Developments
  109. 7.19 Tigermed
  110. 7.19.1 Tigermed Company Information
  111. 7.19.2 Tigermed Business Overview
  112. 7.19.3 Tigermed Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Tigermed Biocompatibility Testing Product Portfolio
  114. 7.19.5 Tigermed Recent Developments
  115. 7.20 King Rock
  116. 7.20.1 King Rock Company Information
  117. 7.20.2 King Rock Business Overview
  118. 7.20.3 King Rock Biocompatibility Testing Revenue and Gross Margin (2021-2026)
  119. 7.20.4 King Rock Biocompatibility Testing Product Portfolio
  120. 7.20.5 King Rock Recent Developments
8 North America
  1. 8.1 North America Biocompatibility Testing Revenue (2021-2032)
  2. 8.2 North America Biocompatibility Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Biocompatibility Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Biocompatibility Testing Revenue by Type (2027-2032)
  5. 8.3 North America Biocompatibility Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Biocompatibility Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Biocompatibility Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Biocompatibility Testing Revenue by Application (2027-2032)
  9. 8.5 North America Biocompatibility Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Biocompatibility Testing Revenue by Country
  11. 8.6.1 North America Biocompatibility Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biocompatibility Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Biocompatibility Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biocompatibility Testing Revenue (2021-2032)
  2. 9.2 Europe Biocompatibility Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biocompatibility Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biocompatibility Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Biocompatibility Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biocompatibility Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biocompatibility Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biocompatibility Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Biocompatibility Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biocompatibility Testing Revenue by Country
  11. 9.6.1 Europe Biocompatibility Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biocompatibility Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biocompatibility Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biocompatibility Testing Revenue (2021-2032)
  2. 10.2 China Biocompatibility Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Biocompatibility Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Biocompatibility Testing Revenue by Type (2027-2032)
  5. 10.3 China Biocompatibility Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Biocompatibility Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Biocompatibility Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Biocompatibility Testing Revenue by Application (2027-2032)
  9. 10.5 China Biocompatibility Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biocompatibility Testing Revenue (2021-2032)
  2. 11.2 Asia Biocompatibility Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biocompatibility Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biocompatibility Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Biocompatibility Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biocompatibility Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biocompatibility Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biocompatibility Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Biocompatibility Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biocompatibility Testing Revenue by Country
  11. 11.6.1 Asia Biocompatibility Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biocompatibility Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biocompatibility Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biocompatibility Testing Revenue (2021-2032)
  2. 12.2 SAMEA Biocompatibility Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biocompatibility Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biocompatibility Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biocompatibility Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biocompatibility Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biocompatibility Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biocompatibility Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biocompatibility Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biocompatibility Testing Revenue by Country
  11. 12.6.1 SAMEA Biocompatibility Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biocompatibility Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biocompatibility Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst